<DOC>
	<DOCNO>NCT00925119</DOCNO>
	<brief_summary>Beta-blockers medication use treat cardiovascular disease ( CVD ) symptom , include high blood pressure chest pain . People diabetes receive beta-blockers may experience adverse health effect , exact cause happen remain unknown . This study examine genetic factor may influence atenolol , beta-blocker medication , affect fat breakdown , blood sugar level , heart function people type 2 diabetes .</brief_summary>
	<brief_title>Examining Genetic Influence Response Beta-Blocker Medications People With Type 2 Diabetes</brief_title>
	<detailed_description>People diabetes develop CVD bad health outcome people without diabetes develop CVD . Beta-blockers medication use treat high blood pressure , angina ( i.e. , chest pain ) , arrhythmias , CVD condition . While beta-blockers effective treating condition , may also damage effect cholesterol glucose level , thereby possibly lessen ability prevent CVD event people diabetes . It important identify patient may benefit receive beta-blocker medication . Genetic factor may influence people respond beta-blocker medication . The purpose study evaluate influence genetic variation beta-blocker-induced change insulin sensitivity , fat breakdown , heart function people type 2 diabetes . This study enroll people type 2 diabetes . At series three baseline study visit , participant blood collection , glucose tolerance test , echocardiogram obtain image heart , biopsy muscle thigh fat stomach . All participant receive atenolol day 8 week . During Week 1 , participant receive low dose atenolol . They attend study visit end Week 1 , study researcher examine well participant tolerate medication . If atenolol well tolerate , dose increase . Study researcher call participant 1 week dosage change monitor side effect . Blood collection occur study visit Week 4 . At Week 8 , participant attend three study visit repeat baseline testing . Participants slowly taper atenolol 1-week period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<criteria>Type 2 diabetes 1 year study entry Insulin therapy Treatment betablocker 30 day study entry Asthma Chronic obstructive pulmonary disease ( COPD ) Greater first degree heart block Heart rate le 60 bpm Systolic blood pressure le 90 mm Hg Raynaud 's phenomenon Known history angina , heart attack , heart failure , coronary revascularization , automatic implantable cardioverter defibrillator Pregnant Creatinine clearance le 35 ml/min Hematologic dysfunction ( white blood cell [ WBC ] count less 3000 hematocrit le 28 % ) Allergy amide anesthetic</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Atenolol</keyword>
	<keyword>Genetic</keyword>
</DOC>